Thus, although our studies shed further light on possible causes of IBD in LRBA-deficient patients and suggest it is a disease with multiple causes, there is still the possibility that in humans SHIP1 agonists might be able to mitigate the disease. Here, INPP5D is linked to inflammatory bowel disease.